Focus: Stereotaxis is a public medical device company specializing in surgical navigation systems for cardiac electrophysiology and interventional cardiology procedures. The company operates at modest scale with $27M in annual revenue and focuses on magnetic navigation-guided catheter technologies.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Stereotaxis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Stereotaxis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Stereotaxis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Stereotaxis: A Real Product Story, But The Stock Already Prices In Success (NYSE:STXS) - Seeking Alpha
Stereotaxis: A Real Product Story, But The Stock Already Prices In Success (NYSE:STXS) Seeking Alpha
STXS|Stereotaxis Inc|Price:1.395|Chg%:+0.035 - TradingKey
STXS|Stereotaxis Inc|Price:1.395|Chg%:+0.035 TradingKey
Penumbra CAVT Platform Receives FDA Clearance - dicardiology.com
Penumbra CAVT Platform Receives FDA Clearance dicardiology.com
Stereotaxis’ Catheter Earns Early Clinical Success Following FDA Approval - dicardiology.com
Stereotaxis’ Catheter Earns Early Clinical Success Following FDA Approval dicardiology.com
First US patients get new catheter for hard-to-treat heart rhythm - Stock Titan
First US patients get new catheter for hard-to-treat heart rhythm Stock Titan
Stereotaxis Announces First MAGiC Procedures in the United States - GlobeNewswire
Stereotaxis Announces First MAGiC Procedures in the United States GlobeNewswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Troubles in the Pocket: Evidence- and Experience-Based Multidisciplinary Expert Consensus Recommendations for Implantable Pulse Generator Placement and Management of Associated Inconveniences.
Brainstem cavernous malformations: observation, microsurgical resection or stereotactic radiosurgery.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo